000227.KS

Yuyu Pharma, Inc.
KSEKRWEQUITY DELAYED
Last price
6,850.00
▼ 270.00 (3.79%)
MARKET ·

Price

1D H L Range Vol
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
Prev close
7,120.00
Day high
Day low
Volume
Market cap
P/E (TTM)
52W range
— – 12,400.00

Trailing performance

Price return · vs SPY
Returnvs SPY
1W
-12.18% -11.0%
1M
-8.54% -11.9%
3M
-35.50% -37.9%
6M
-35.62% -47.5%
YTD
-38.73% -50.7%
1Y
-34.82% -55.0%
3Y
-41.80% -116.8%
5Y

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Free account

3 more panels on 000227.KS open with an account.

Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.

Fundamentals

TTM · reported
Market cap
Enterprise value
Revenue (TTM)
Gross profit
EBITDA
Net income
EPS (TTM)
Free cash flow
Total cash
Total debt
Book value / share
Shares outstanding
Float
Short % of float
Dividend yield
Beta (5Y)

Valuation & profitability ratios

Account required
Trailing P/E
Forward P/E
PEG ratio
Price / sales
Price / book
EV / revenue
EV / EBITDA
Gross margin
Operating margin
Profit margin
Return on equity
Return on assets
Debt / equity
Current ratio
Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Financial statements

As reported · 5 years · 6 quarters
Blank means not reported, not zero
Line item2025202420232022YoY
Total revenue $140.88B$133.15B$137.21B$138.88B +5.8%
Operating revenue $140.88B$133.15B$137.21B$138.88B +5.8%
Cost of revenue $86.94B$81.44B$88.31B$85.57B +6.8%
Gross profit $53.94B$51.70B$48.90B$53.31B +4.3%
Research & development $3.61B$2.78B$7.19B$8.62B +30.0%
Selling, general & admin $19.60B$17.92B$15.90B$19.99B +9.4%
Total operating expense $42.92B$39.12B$48.53B$53.91B +9.7%
Operating income $11.02B$12.58B$364.54M-$592.11M -12.4%
Net interest income -$2.79B-$2.21B-$1.66B-$2.02B -26.2%
Pre-tax income $9.48B$9.98B-$5.44B-$3.81B -5.0%
Tax provision $365.96M-$304.67M$98.44M$615.02M +220.1%
Net income $8.15B$8.72B-$7.18B-$5.99B -6.5%
Net income to common $8.15B$8.72B-$7.18B-$5.99B -6.5%
EBIT $11.96B$13.20B-$2.89B-$1.23B -9.4%
EBITDA $17.57B$18.87B$2.72B$3.80B -6.9%

Analyst targets & ownership

Account required
Mean target
High target
Low target
Implied upside
Analyst count
Consensus
Strong buy / Buy— / —
Hold
Sell / Strong sell— / —
Held by insiders
Held by institutions
Institutions holding
Free account required

Price targets, consensus spread, insider and institutional ownership.

Moving averages & technicals

Computed from 2Y daily closes
SMA 10
7,415.00
-7.62% from price
SMA 20
7,297.00
-6.13% from price
SMA 50
8,373.40
-18.19% from price
SMA 100
9,539.40
-28.19% from price
SMA 200
10,153.75
-32.54% from price
EMA 12
7,363.41
-6.97% from price
EMA 26
7,625.85
-10.17% from price
EMA 50
8,220.27
-16.67% from price
RSI (14)
39.0
Neutral
MACD (12,26,9)
-262.44
Hist 40.16
ATR (14)
396.43
5.79% of price
Realised vol 30D
104.1%
Annualised
Bollinger upper
7,991.15
20, 2σ
Bollinger lower
6,602.85
20, 2σ
50 / 200 cross
Death
8,373.40 vs 10,153.75
Trend bias
Below 200
-32.54%

Options chain

Account required
Expiry
Spot 6,850.00
Calls
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Puts
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Risk profile

Daily returns · 1Y window
Beta vs SPY
0.22
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
104.1%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-46.0%
Peak to trough
Max drawdown 5Y
-76.3%
Peak to trough
ATR 14
396.43
5.79% of price
Beta (reported)
5Y monthly, from filing

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.